FDA Approves New Therapy for Rare Disease Affecting Optic Nerve, Spinal Cord

FDA approved Uplizna for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are positive for antibody called AQP4. NMOSD is a rare autoimmune disease that attacks the optic nerves and spinal cord. Uplizna is the second approved treatment for the disorder.

Source: FDA Center for Drug Evaluation and Research - What's New - June 11, 2020 Category: Drugs & Pharmacology Authors: FDA Source Type: news